Clinical Trial Update: Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure [Phase 3]

View source ↗

Summary

A Phase 3 study of Rexlemestrocel-L for chronic heart failure has completed and posted efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Rexlemestrocel-L (allogeneic mesenchymal precursor cells)

Snippet

Sponsor: Mesoblast, Inc. | Conditions: Chronic Heart Failure | Phase 3 | Status: COMPLETED | Results posted: 2026-03-23